TrialCancer immunology, immunotherapy : CII1995

Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.

L T Vlasveld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.